CD8A and plasma cell myeloma: ImmTAC-NYE was able to activate and redirect normal CD8+ T cells to a range of cell lines derived from melanoma (A375, Mel624, and SK-Mel-37), myeloma (U266), and EBV transformed B cells (IM9), in addition to freshly isolated lung cancer cells.